Rennie Orange Flavour
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Rennie Orange Flavour
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Calcium Carbonate 500mg
Also contains sucrose and Ponceau 4R (E124)
For full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable Tablet
A square orange occasionally spotted tablet with rounded corners, bevelled edges and concave faces.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the symptomatic relief of indigestion, heartburn, hyperacidity, flatulence, upset stomach, dyspepsia, biliousness, over indulgence in food and drink, indigestion during pregnancy, acid indigestion, nervous indigestion.
4.2 Posology and method of administration
Tablets to be taken orally, sucked or chewed.
Adults and Two tablets to be sucked or chewed as a single dose,
children over 12 preferably to be taken one hour after meals and before
years: going to bed but also in between in case of heartburn or
gastric pain. A maximum daily dose of 8 g calcium carbonate, corresponding to 16 tablets, a day must not be exceeded.
As with all antacids, if symptoms persist despite 14 days of continuous therapy, diagnostic measures are strongly recommended in order to rule out a more serious disease.
4.3. Contraindications
Rennie should not be administered to patients with:
• Hypersensitivity to any of the ingredients of the product
• Hypercalcaemia and/or conditions resulting in hypercalcaemia
• Nephrolithiasis due to calculi containing calcium deposits
• Severe renal insufficiency
• Hypophosphataemia
4.4 Special warnings and precautions for use
• Prolonged use should be avoided.
• The stated dose should not be exceeded. If, after 14 days of treatment, symptoms persist or only partly disappear, the patient should consult a doctor.
• Caution should be exercised in patients with mild to moderate impairment of renal function (See section 4.3 - contraindication in severe renal insufficiency). If Rennie is used in such patients, plasma calcium and phosphate levels should be regularly monitored.
• Long term use at high doses can result in undesirable effects such as hypercalcaemia and milk-alkali syndrome, especially in patients with renal insufficiency.
• Rennie should not be used in patients with hypercalciuria (see also section 4.3). Prolonged use increases the risk of formation of renal calculi.
• This product should not be taken with large amounts of milk or dairy products.
• Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
• Ponceau 4R (E124) may cause allergic reactions.
4.5 Interaction with other medicinal products and other forms of interaction
Changes in gastric acidity, such as that caused by the ingestion of antacids, can affect the rate and degree to which some concurrently administered medicines are absorbed.
• It has been shown that antacids which contain calcium may form complexes with certain substances e.g., antibiotics (such as tetracyclines and quinolones), and cardiac glycosides (e.g. digoxin), levothyroxine, and eltrombopag, resulting in decreased absorption. This should be borne in mind when concomitant administration is considered.
• Calcium salts can impede the absorption of phosphates, fluorides and iron-containing products.
• Thiazide diuretics reduce the urinary excretion of calcium. Due to an increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.
Therefore it is preferable to take the antacid separately from other drugs, allowing at least 4 hours before or after taking eltrombopag and a 1-2 hour interval for all other drugs.
4.6. Fertility, pregnancy and lactation
No increased risk of congenital defects has been observed after the use of this product during pregnancy and it can be used during pregnancy and lactation if taken as instructed but prolonged intake of high dosages should be avoided. Pregnant women should limit the use of these products to the maximum recommended daily doses (see Section 4.2).
During pregnancy and lactation, it has to be taken into account that the tablets provide a substantial amount of calcium in addition to dietary calcium intake. For this reason, pregnant women should strictly limit their use of tablets to the maximum recommended daily dose and avoid concomitant, excessive intake of milk and dairy products. This warning is to prevent calcium overload which might result in milk-alkali syndrome.
4.7 Effects on ability to drive and use machines
No effects on ability to drive and use machines have been observed.
4.8 Undesirable effects
The listed adverse drug reactions are based on spontaneous reports, thus an organisation according to CIOMS III categories of frequency is not possible.
Immune System Disorders:
Hypersensitivity reactions have very rarely been reported. Clinical symptoms may include rash, urticaria, angioedema and anaphylaxis.
Metabolism and Nutrition Disorders:
Especially in patients with impaired renal function, prolonged use of high doses can result in hypercalcaemia and alkalosis which may give rise to gastric symptoms and muscular weakness (see below).
Gastrointestinal Disorders:
Nausea, vomiting, stomach discomfort and diarrhoea may occur.
Musculoskeletal and Connective Tissue Disorders:
Muscular weakness may occur.
Undesirable effects occurring in the context of milk-alkali syndrome (see 4.9):
Gastrointestinal Disorders:
Ageusia may occur in the context of milk-alkali syndrome.
General Disorders and Administration Site Conditions:
Calcinosis and asthenia may occur in the context of milk-alkali syndrome.
Nervous System Disorders:
Headache may occur in the context of milk-alkali syndrome.
Renal and Urinary Disorders:
Azotemia may occur in the context of milk-alkali syndrome.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Especially in patients with impaired renal function, prolonged use of high doses of calcium carbonate can result in renal insufficiency, hypercalcaemia and alkalosis which may give rise to gastrointestinal symptoms (nausea, vomiting, constipation) and muscular weakness. In these cases, the intake of the product should be stopped and adequate fluid intake encouraged. In severe cases of overdosage (e.g. milk-alkali syndrome), a health care professional must be consulted because other measures of rehydration (e.g. infusions) might be necessary.
5 PHARMACOLOGICAL PROPERTIES
5.1
Pharmacodynamic properties
Pharmacotherapeutic Classification: Antacids ATC codes: Calcium carbonate: A02AC01
Calcium carbonate reacts with excess acid in the gastric juice to produce soluble chloride.
CaCO3 +2HCl -» CaCl2 + H2O + CO2
Calcium carbonate has a rapid and powerful neutralising action.
In healthy volunteers, a significant increase in the pH of stomach contents above baseline pH was achieved between 1 and 6 minutes after dosing.
5.2 Pharmacokinetic properties
A small amount of calcium may be absorbed, but in healthy subjects is usually rapidly excreted by the kidney. The soluble chloride produced by the reaction of calcium with gastric acid reacts, in turn, with intestinal, biliary and pancreatic secretions to form insoluble salts, which are excreted in the faeces.
5.3. Preclinical safety data
There is no information of relevance to the safety assessment in addition to what is stated in other parts of the Summary of Product Characteristics.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sucrose Pregelatinised Maize Starch Potato Starch Anhydrous Citric Acid Purified Talc Magnesium Stearate Saccharin Quinoline Yellow (E104) Ponceau 4R (E124) Orange Flavour.
6.2 Incompatibilities
None.
6.3
Shelf life
36 months.
6.4 Special precautions for storage
Do not store above 25 °C
6.5 Nature and contents of container
Tablets are packed in clear styrolex bottles with polypropylene lids, containing 30, 70, 100, or 150 tablets.
Alternatively, 8 tablets are roll wrapped in laminated foil.
Alternatively, tablets are packed in aluminium foil/pvc blister strips with 4, 8, or 12 tablets per strip. 1, 2, 3, 4, 6, 8, 10 or 12 strips are
Placed in a cardboard carton (8, 12, 24, 32, 48, 64, 72, 80, 96, or 120 tablets per carton), which may contain one or more cut-out "windows".
Alternatively one strip of 8 tablets is presented in a cardboard sample wallet which may contain one or more cut-out "windows".
Pack sizes: 8, 12, 24, 30, 32, 48, 60, 64, 70, 72, 80, 96,100, 120, 150.
6.6 Special precautions for disposal
None
7 MARKETING AUTHORISATION HOLDER
Bayer plc, Consumer Care Division
Bayer House
Strawberry Hill
Newbury
Berkshire
RG14 1JA
UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 00010/0354
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
1/07/2005
10
DATE OF REVISION OF THE TEXT
06/07/2015